Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i3.20
pages 239-254

Proteomics for the Development of Vaccines and Therapeutics

Vito G. DelVecchio
Vital Probes, Inc., Mayfeld, Pennsylvania
Mark A. Sabato
Vital Probes, Inc., Mayfeld, Pennsylvania
Jessica Trichilo
Vital Probes, Inc., Mayfeld, Pennsylvania
Clarissa Dake
Vital Probes, Inc., Mayfeld, Pennsylvania
Paul Grewal
Vital Probes, Inc., Mayfeld, Pennsylvania
Tim Alefantis
Vital Probes, Inc


Proteomics permits the large-scale and high-throughput analysis of proteins and has become a powerful tool with which to study the pathogenic mechanisms of bacteria. It not only provides a metabolic snapshot at a particular moment in the life of a pathogen, but can also determine where a protein resides, its function, whether it is secreted, and its interactions with other proteins, including those of the host. Comparative proteomics can yield important information on the differences between attenuated and pathogenic organisms and whether a protein is conserved among various strains. Our laboratory has utilized traditional and novel techniques to investigate the global and subproteomes of Bacillus anthracis as they relate to vaccine and therapeutic development. Recently, our efforts have focused on the use of mass spectrometry for B-cell epitope discovery and identification of components of a pathogen that interact with host proteins. Development of vaccines and therapeutics based on proteomic data in combination with novel adjuvants and delivery systems will be presented.